PRGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Perrigo Co's PE Ratio without NRI is 11.02. Perrigo Co's 5-Year EBITDA growth rate is -10.20%. Therefore, Perrigo Co's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Perrigo Co's PEG Ratio or its related term are showing as below:
During the past 13 years, Perrigo Co's highest PEG Ratio was 23.81. The lowest was 3.41. And the median was 12.08.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Perrigo Co's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Perrigo Co Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Perrigo Co's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Perrigo Co's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | 11.024096385542 | / | -10.20 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Perrigo Co (NYSE:PRGO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Perrigo Co's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Katherine C. Doyle | director | 100 ABBOTT PARK ROAD, AP6C-1N D032L, ABBOTT PARK IL 60064 |
Ronald Craig Janish | officer: EVP, Global Op. & Supply Chain | PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Svend Andersen | director | C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Alison Ives | officer: EVP & Chief Scientific Officer | C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Robert Willis | officer: Acting CHRO | C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Patrick Lockwood-taylor | director, officer: CEO | C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503 |
Eduardo Guarita Bezerra | officer: EVP & Chief Financial Officer | C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134 |
Julia M Brown | director | C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001 |
Triona Schmelter | officer: EVP & President CSCA | 2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523 |
Geoffrey M. Parker | director | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Murray S Kessler | director, officer: CEO | 714 GREEN VALLEY ROAD, GREENSBORO NC 27408 |
Thomas Farrington | officer: Senior VP and CIO | 4012 W. CANTERBURY CT., NEQUON WI 53092 |
Dillard James E Iii | officer: EVP, Chief Scientific Officer | 6601 WEST BROAD STREET, RICHMOND VA 23230 |
Grainne Quinn | officer: EVP, Chief Medical Officer | PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Albert Manzone | director | C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000 |
From GuruFocus
By GuruFocus Research • 09-11-2024
By PRNewswire • 09-17-2024
By PRNewswire • 09-12-2024
By GuruFocus Research • 08-03-2024
By PRNewswire • 05-28-2024
By GuruFocus Research • 05-07-2024
By PRNewswire • 09-26-2024
By PRNewswire • 10-15-2024
By PRNewswire • 07-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.